Success Metrics

Clinical Success Rate
91.8%

Based on 270 completed trials

Completion Rate
92%(270/294)
Active Trials
30(7%)
Results Posted
33%(90 trials)
Terminated
24(6%)

Phase Distribution

Ph phase_3
80
20%
Ph early_phase_1
3
1%
Ph phase_1
57
14%
Ph phase_2
54
13%
Ph phase_4
165
41%
Ph not_applicable
26
6%

Phase Distribution

60

Early Stage

54

Mid Stage

245

Late Stage

Phase Distribution385 total trials
Early Phase 1First-in-human
3(0.8%)
Phase 1Safety & dosage
57(14.8%)
Phase 2Efficacy & side effects
54(14.0%)
Phase 3Large-scale testing
80(20.8%)
Phase 4Post-market surveillance
165(42.9%)
N/ANon-phased studies
26(6.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.1%

270 of 303 finished

Non-Completion Rate

10.9%

33 ended early

Currently Active

30

trials recruiting

Total Trials

407

all time

Status Distribution
Active(37)
Completed(270)
Terminated(33)
Other(67)

Detailed Status

Completed270
unknown67
Terminated24
Recruiting23
Withdrawn9
Not yet recruiting7

Development Timeline

Analytics

Development Status

Total Trials
407
Active
30
Success Rate
91.8%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (0.8%)
Phase 157 (14.8%)
Phase 254 (14.0%)
Phase 380 (20.8%)
Phase 4165 (42.9%)
N/A26 (6.8%)

Trials by Status

recruiting236%
completed27066%
terminated246%
not_yet_recruiting72%
unknown6716%
withdrawn92%
active_not_recruiting72%

Recent Activity

Clinical Trials (407)

Showing 20 of 407 trialsScroll for more
NCT03188705Phase 4

CES1 Carriers in the PAPI Study

Completed
NCT06577519Phase 3

Efficacy and Safety Study of Vicagrel in Patients With Acute Coronary Syndrome (ACS) Undergoing Percutaneous Coronary Intervention (PCI)

Recruiting
NCT03161678Phase 4

CES1 Crossover Trial of Clopidogrel and Ticagrelor

Completed
NCT07597239Not Applicable

Thromboelastography With Platelet Mapping to Guide Antiplatelet Therapy After Lower Extremity Revascularization

Active Not Recruiting
NCT07720934Not Applicable

A Pilot Study to Investigate Platelet Reactivity in Patients With Elevated Lipoprotein(a) and Its Response to Antiplatelet Therapy

Not Yet Recruiting
NCT07610577

Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction

Completed
NCT05566301

Multicentric Study on Clopidogrel Resistance in DAPT for CAS (MULTI-RESCLOSA)

Recruiting
NCT07619885Phase 1

The Pharmacokinetics and Pharmacodynamics Study of Evategrel CG-0255 Besylate)and Plavix® in Healthy Participants

Recruiting
NCT04695106Phase 4

Dual Antithrombotic Therapy With Dabigatran and Ticagrelor in Patients With ACS and Non-valvular AF Undergoing PCI

Recruiting
NCT07644234Phase 4

Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke

Not Yet Recruiting
NCT06692933Early Phase 1

Effects of a Hemp Product on the Pharmacokinetics and Pharmacodynamics of Clopidogrel

Recruiting
NCT04981041Phase 4

Escalated Single Platelet Inhibition for One Month Plus NOAC in Patients With Atrial Fibrillation and ACS Undergoing PCI

Completed
NCT02505399Phase 4

TIcagrelor in Rotational Atherectomy to Reduce TROPonin Enhancement

Completed
NCT07613840Not Applicable

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

Recruiting
NCT07582835Phase 3

Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.

Recruiting
NCT04770012Phase 3

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Recruiting
NCT06402747Phase 4

Clopidogrel Versus Cilostazol on Vessels

Recruiting
NCT02044250Phase 4

Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM)

Completed
NCT06757764Phase 4

The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis

Recruiting
NCT06650488Phase 4

Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
407